Find Oncology Drugs in Phase I/II Clinical Development in GERMANY

Lead Product(s): OR2805

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: OncoResponse

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 16, 2020

Details:

Under the agreement, Just – Evotec Biologics will leverage its integrated technology platform, J.DESIGN, to provide OncoResponse with services to accelerate OR2805 into the clinic.

Lead Product(s): Autologous dendritic cell vaccine

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

Final topline primary outcomes: DC vaccinations safe and feasible at 24 months of treatment Topline secondary outcomes: Overall survival rate of 80%, progression-free survival rate (PFS) of 55%.